• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将线粒体 DNA 突变置于 I 型子宫内膜癌的进展模型中。

Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.

机构信息

Department of Biochemistry and Molecular Biology E.Quagliariello, University of Bari, 70126 Bari, Italy.

出版信息

Hum Mol Genet. 2011 Jun 15;20(12):2394-405. doi: 10.1093/hmg/ddr146. Epub 2011 Apr 5.

DOI:10.1093/hmg/ddr146
PMID:21470976
Abstract

Mitochondrial DNA (mtDNA) mutations have been described in almost all types of cancer. However, their exact role and timing of occurrence during tumor development and progression are still a matter of debate. A Vogelstein-like model of progression is well established for endometrial carcinoma (EC), however, mtDNA has been scarcely investigated in these tumors despite the fact that mitochondrial biogenesis increase has been shown to be a hallmark of type I EC. Here, we screened a panel of 23 type I EC tissues and matched typical hyperplasia for mutations in mtDNA and in four oncosupressors/oncogenes, namely PTEN, KRAS, CTNNB1 and TP53. Overall, mtDNA mutations were identified in 69% of cases, while mutational events in nuclear genes occurred in 56% of the cases, indicating that mtDNA mutations may precede the genetic instability of these genes canonically involved in progression from hyperplasia to tumor. Protein expression analysis revealed an increase in mitochondrial biogenesis and activation of oxidative stress response mechanisms in tumor tissues, but not in hyperplasia, in correlation with the occurrence of pathogenic mtDNA mutations. Our results point out an involvement of mtDNA mutations in EC progression and explain the increase in mitochondrial biogenesis of type I EC. Last, since mtDNA mutations occur after hyperplasia, their potential role in contributing to genetic instability may be envisioned.

摘要

线粒体 DNA(mtDNA)突变几乎存在于所有类型的癌症中。然而,它们在肿瘤发生和发展过程中的具体作用和发生时间仍然存在争议。子宫内膜癌(EC)的进展具有 Vogelstein 样模型,然而,尽管已经表明线粒体生物发生的增加是 I 型 EC 的标志,但在这些肿瘤中很少研究 mtDNA。在这里,我们筛选了一组 23 种 I 型 EC 组织和匹配的典型增生,以检测 mtDNA 和四个抑癌基因/原癌基因(即 PTEN、KRAS、CTNNB1 和 TP53)中的突变。总的来说,mtDNA 突变在 69%的病例中被鉴定出来,而核基因中的突变事件在 56%的病例中发生,这表明 mtDNA 突变可能先于这些基因的遗传不稳定性发生,这些基因通常参与从增生到肿瘤的进展。蛋白质表达分析显示,肿瘤组织中线粒体生物发生的增加和氧化应激反应机制的激活,但在增生中没有,这与致病性 mtDNA 突变的发生相关。我们的结果表明 mtDNA 突变参与了 EC 的进展,并解释了 I 型 EC 中线粒体生物发生的增加。最后,由于 mtDNA 突变发生在增生之后,因此可以设想它们在导致遗传不稳定性方面的潜在作用。

相似文献

1
Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.将线粒体 DNA 突变置于 I 型子宫内膜癌的进展模型中。
Hum Mol Genet. 2011 Jun 15;20(12):2394-405. doi: 10.1093/hmg/ddr146. Epub 2011 Apr 5.
2
Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.子宫内膜癌中不同的基因改变集暗示了肿瘤发生的不同模式。
Cancer. 2002 May 1;94(9):2369-79. doi: 10.1002/cncr.10498.
3
Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.子宫内膜增生和癌中KRAS癌基因的突变
Folia Histochem Cytobiol. 2009;47(1):65-8. doi: 10.2478/v10042-009-0014-2.
4
Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.子宫内膜癌的分子特征:一项评估微卫星不稳定性、MLH1 高甲基化、DNA 错配修复蛋白表达以及 PTEN、PIK3CA、KRAS 和 BRAF 突变分析的相关性研究。
Int J Gynecol Pathol. 2012 May;31(3):195-205. doi: 10.1097/PGP.0b013e318231fc51.
5
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.通过联合分析 MSI、PI3K-AKT、Wnt/β-catenin 和 P53 通路激活,改善子宫内膜癌的风险评估。
Gynecol Oncol. 2012 Sep;126(3):466-73. doi: 10.1016/j.ygyno.2012.05.012. Epub 2012 May 15.
6
Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.乳腺癌患者中 TP53 调控通路甲基化谱和 mtDNA 改变与 TP53 基因突变缺失的关系。
Hum Mol Genet. 2010 Aug 1;19(15):2936-46. doi: 10.1093/hmg/ddq199. Epub 2010 May 12.
7
Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.卵巢和子宫内膜样腺癌在微卫星不稳定性、PTEN表达及ARID1A表达方面具有不同特征。
Histopathology. 2015 Mar;66(4):517-28. doi: 10.1111/his.12543. Epub 2014 Dec 22.
8
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.对原发性子宫内膜癌中的 PIK3CA、PTEN、KRAS、FBXW7 和 TP53 突变进行高通量检测。
Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4.
9
Pathology of Endometrial Carcinoma.子宫内膜癌的病理学
Adv Exp Med Biol. 2017;943:75-96. doi: 10.1007/978-3-319-43139-0_3.
10
Efficacy of liquid-based genetic diagnosis of endometrial cancer.液基基因诊断子宫内膜癌的疗效。
Cancer Sci. 2018 Dec;109(12):4025-4032. doi: 10.1111/cas.13819. Epub 2018 Oct 26.

引用本文的文献

1
Mitophagy in gynecological malignancies: roles, advances, and therapeutic potential.妇科恶性肿瘤中的线粒体自噬:作用、进展及治疗潜力
Cell Death Discov. 2024 Dec 5;10(1):488. doi: 10.1038/s41420-024-02259-x.
2
Our current understanding of the biological impact of endometrial cancer mtDNA genome mutations and their potential use as a biomarker.我们目前对子宫内膜癌线粒体DNA基因组突变的生物学影响及其作为生物标志物的潜在用途的理解。
Front Oncol. 2024 Jun 27;14:1394699. doi: 10.3389/fonc.2024.1394699. eCollection 2024.
3
Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
线粒体-溶酶体通讯缺陷诱导线粒体衍生小泡的分泌并驱动卵巢癌细胞的化疗耐药性。
Cell Commun Signal. 2024 Mar 6;22(1):165. doi: 10.1186/s12964-024-01507-y.
4
Roles of MT-ND1 in Cancer.线粒体编码的烟酰胺腺嘌呤二核苷酸脱氢酶1(MT-ND1)在癌症中的作用。
Curr Med Sci. 2023 Oct;43(5):869-878. doi: 10.1007/s11596-023-2771-0. Epub 2023 Aug 29.
5
Novel insights into tumorigenesis and prognosis of endometrial cancer through systematic investigation and validation on mitophagy-related signature.通过对噬线粒体相关特征的系统研究和验证,深入了解子宫内膜癌的发生机制和预后。
Hum Cell. 2023 Jul;36(4):1548-1563. doi: 10.1007/s13577-023-00920-8. Epub 2023 Jun 2.
6
The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies.基因突变在特定肿瘤(乳腺癌和妇科恶性肿瘤)线粒体驱动的肿瘤生长中的作用
Life (Basel). 2023 Apr 12;13(4):996. doi: 10.3390/life13040996.
7
Identification of Somatic Mitochondrial DNA Mutations, Heteroplasmy, and Increased Levels of Catenanes in Tumor Specimens Obtained from Three Endometrial Cancer Patients.从三名子宫内膜癌患者获取的肿瘤标本中体细胞线粒体DNA突变、异质性及连环体水平升高的鉴定
Life (Basel). 2022 Apr 9;12(4):562. doi: 10.3390/life12040562.
8
Respiratory Complex I dysfunction in cancer: from a maze of cellular adaptive responses to potential therapeutic strategies.癌症中的呼吸复合物 I 功能障碍:从细胞适应性反应的迷宫到潜在的治疗策略。
FEBS J. 2022 Dec;289(24):8003-8019. doi: 10.1111/febs.16218. Epub 2021 Oct 18.
9
Mitochondrial Caseinolytic Protease P: A Possible Novel Prognostic Marker and Therapeutic Target in Cancer.线粒体蛋白酶体 P:癌症中一种潜在的新型预后标志物和治疗靶点。
Int J Mol Sci. 2021 Jun 9;22(12):6228. doi: 10.3390/ijms22126228.
10
The Great Escape: The Power of Cancer Stem Cells to Evade Programmed Cell Death.《大逃脱:癌症干细胞逃避程序性细胞死亡的能力》
Cancers (Basel). 2021 Jan 17;13(2):328. doi: 10.3390/cancers13020328.